Nicorandil

A potassium channel opening drug for treatment of ischemic heart disease

Marc Goldschmidt, Brian R. Landzberg, William H. Frishman

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Nicorandil is the first oral potassium channel activating drug to be used for the treatment of symptomatic coronary artery disease. It appears to relax vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and, like nitrates, through an increase in intracellular cyclic GMP. In addition, nicorandil, in a nitrate-like manner, dilates normal and stenotic coronary arteries and reduces both ventricular preload and afterload. In contrast to nitrates, however, nicorandil does not appear to cause tolerance with long-term administration. In placebo and comparison clinical trials, nicorandil has demonstrated some efficacy and safety in patients with both stable and vasospastic angina pectoris, and it was found to be a myocardial protective agent in animal studies. The antianginal activity of nicorandil, however, is relatively short lived after dosing, which will necessitate the development of extended release formulations of the drug.

Original languageEnglish (US)
Pages (from-to)559-572
Number of pages14
JournalJournal of Clinical Pharmacology
Volume36
Issue number7
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Nicorandil
Potassium Channels
Myocardial Ischemia
Nitrates
Pharmaceutical Preparations
Therapeutics
Protective Agents
Drug Compounding
Stable Angina
Cyclic GMP
Patient Safety
Vascular Smooth Muscle
Coronary Artery Disease
Coronary Vessels
Potassium
Placebos
Clinical Trials
Membranes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Goldschmidt, Marc ; Landzberg, Brian R. ; Frishman, William H. / Nicorandil : A potassium channel opening drug for treatment of ischemic heart disease. In: Journal of Clinical Pharmacology. 1996 ; Vol. 36, No. 7. pp. 559-572.
@article{13d105ec17b14e1c8d21f5ff3db9bbd6,
title = "Nicorandil: A potassium channel opening drug for treatment of ischemic heart disease",
abstract = "Nicorandil is the first oral potassium channel activating drug to be used for the treatment of symptomatic coronary artery disease. It appears to relax vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and, like nitrates, through an increase in intracellular cyclic GMP. In addition, nicorandil, in a nitrate-like manner, dilates normal and stenotic coronary arteries and reduces both ventricular preload and afterload. In contrast to nitrates, however, nicorandil does not appear to cause tolerance with long-term administration. In placebo and comparison clinical trials, nicorandil has demonstrated some efficacy and safety in patients with both stable and vasospastic angina pectoris, and it was found to be a myocardial protective agent in animal studies. The antianginal activity of nicorandil, however, is relatively short lived after dosing, which will necessitate the development of extended release formulations of the drug.",
author = "Marc Goldschmidt and Landzberg, {Brian R.} and Frishman, {William H.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1002/j.1552-4604.1996.tb04219.x",
language = "English (US)",
volume = "36",
pages = "559--572",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "7",

}

Nicorandil : A potassium channel opening drug for treatment of ischemic heart disease. / Goldschmidt, Marc; Landzberg, Brian R.; Frishman, William H.

In: Journal of Clinical Pharmacology, Vol. 36, No. 7, 01.01.1996, p. 559-572.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Nicorandil

T2 - A potassium channel opening drug for treatment of ischemic heart disease

AU - Goldschmidt, Marc

AU - Landzberg, Brian R.

AU - Frishman, William H.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Nicorandil is the first oral potassium channel activating drug to be used for the treatment of symptomatic coronary artery disease. It appears to relax vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and, like nitrates, through an increase in intracellular cyclic GMP. In addition, nicorandil, in a nitrate-like manner, dilates normal and stenotic coronary arteries and reduces both ventricular preload and afterload. In contrast to nitrates, however, nicorandil does not appear to cause tolerance with long-term administration. In placebo and comparison clinical trials, nicorandil has demonstrated some efficacy and safety in patients with both stable and vasospastic angina pectoris, and it was found to be a myocardial protective agent in animal studies. The antianginal activity of nicorandil, however, is relatively short lived after dosing, which will necessitate the development of extended release formulations of the drug.

AB - Nicorandil is the first oral potassium channel activating drug to be used for the treatment of symptomatic coronary artery disease. It appears to relax vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and, like nitrates, through an increase in intracellular cyclic GMP. In addition, nicorandil, in a nitrate-like manner, dilates normal and stenotic coronary arteries and reduces both ventricular preload and afterload. In contrast to nitrates, however, nicorandil does not appear to cause tolerance with long-term administration. In placebo and comparison clinical trials, nicorandil has demonstrated some efficacy and safety in patients with both stable and vasospastic angina pectoris, and it was found to be a myocardial protective agent in animal studies. The antianginal activity of nicorandil, however, is relatively short lived after dosing, which will necessitate the development of extended release formulations of the drug.

UR - http://www.scopus.com/inward/record.url?scp=0029766082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029766082&partnerID=8YFLogxK

U2 - 10.1002/j.1552-4604.1996.tb04219.x

DO - 10.1002/j.1552-4604.1996.tb04219.x

M3 - Review article

VL - 36

SP - 559

EP - 572

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 7

ER -